MorphoSys AG: GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Planegg ,Bayern ,Thomas Biegi ,Julia Neugebauer ,Eamonn Nolan ,Morphosys Agview ,Exchange Commission ,Linkedin ,Twitter ,American College Of Rheumatology ,American College ,Janus Kinase ,Morphosy Annual Report ,Morphosys ,Icensing ,Partner ,Rovides ,Update ,Contrast ,Hase ,Program ,Otilimab ,Moderate ,Evere ,Rheumatoid ,Arthritis ,